A new futuristic glaucoma therapeutic management paradigm

Anusuya Gehlot, Surbhi Raichandni, Neeta Trehan, Mitali Dua, Jitendra Singh, Bhavya Gehlot

Abstract


Glaucoma is a group of diseases, characterized by a progressive form of optic nerve damage. Current studies indicate more selective pathophysiological involvement, thereby targeted therapies are warranted. Although both the prostaglandin analogs and beta blockers are still, most commonly used drugs for glaucoma, due to their efficacy, lack of adverse effects. In addition, a stepped care approach is the corner stone for its management. In addition, attempts have been made to enhance patient compliance and ocular delivery of already available anti-glaucoma drugs such as pilocarpine and timolol maleate. Notable among futuristic treatment options are; novel delivery systems, benzalkonium chloride-free drugs, various glaucoma drainage devices, new targeted therapies and prompt diagnosis plus aggressive treatment, in patients with primary angle closure glaucoma. Promising new focus on vision sparing, greater patient safety and tolerability will provide improved treatment options and long-term preservation of vision and quality of life.


Keywords


Novel delivery systems, Benzalkonium chloride-free drugs, Glaucoma drainage devices, New targeted therapies

Full Text:

PDF

References


Lavik E, Kuehn MH, Kwon YH. Novel drug delivery systems for glaucoma. Eye Lond. 2011;25:578-86.

He XG. Challenge and treatment strategy for ocular surface damage in patients with long term use of antiglaucoma drugs. Zhonghua Yan Ke Za Zhi 2011;47(2):101-4.

Bagnis A, Papadia M, Scotto R, Traverso CE. Antiglaucoma drugs: the role of preservative-free formulations. Saudi J Ophthalmol. 2011;25(4):389-94.

Shetty R. Glaucoma drainage devices. Available at http://www.emedicine.medspace.com/article/1208066. Accessed 22 November 2013.

Thieme H. Current status of epibulbar anti-glaucoma drainage devices in glaucoma surgery. Dtsch Arztebl Int. 2012;109(40):659-64.

Zarbin MA. A new target for glaucoma therapy. JAMA Ophthalmol. 2013.

Fan BJ, Wiggs JL. Glaucoma: genes, phenotypes, and new directions for therapy. J Clin Invest. 2010;120(9):3064-72.